Cargando…
Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis
BACKGROUND: Vitreoretinal lymphoma (VRL) is usually treated with a combination of intraocular methotrexate (ioMTX), high-dose intravenous methotrexate (HD-MTX), or local radiotherapy (RT) as the first options. The effectiveness and safety of monotherapy like bruton’s tyrosine kinase inhibitors (BTKi...
Autores principales: | Gao, Jing, Peng, Xiaoyan, Wang, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664658/ https://www.ncbi.nlm.nih.gov/pubmed/37993841 http://dx.doi.org/10.1186/s12886-023-03226-3 |
Ejemplares similares
-
Vitreoretinal Lymphoma
por: Sobolewska, Bianka, et al.
Publicado: (2021) -
Primary vitreoretinal lymphoma
por: Mulay, Kaustubh, et al.
Publicado: (2015) -
Primary vitreoretinal lymphoma
por: Kalogeropoulos, Dimitrios, et al.
Publicado: (2019) -
Diagnostic efficacy of cell block method for vitreoretinal lymphoma
por: Kase, Satoru, et al.
Publicado: (2016) -
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
por: Wang, Liang, et al.
Publicado: (2021)